reviewed april 2026|next review october 2026|88 physicians psi has verified|113 published studies
PT-141 (Bremelanotide)
PT-141 (bremelanotide) is a melanocortin-4 receptor agonist approved by the FDA as Vyleesi for hypoactive sexual desire disorder in premenopausal women. It is the only approved medication that targets sexual desire through the central nervous system.
Evidence landscape: 113 published studies
113 published items: 24 human studies and 39 animal studies. A focused clinical evidence base supporting the first central-mechanism FDA approval for sexual desire.
- 24 Human
- 39 Animal
- 50 Reviews
FDA-approved as Vyleesi (bremelanotide) for hypoactive sexual desire disorder (HSDD) in premenopausal women. Subcutaneous self-injection, as needed. No more than one dose per 24 hours and 8 doses per month.
The RECONNECT Phase III program enrolled more than 1,200 women. Statistically significant improvement in desire scores and reduction in distress associated with low desire.
The only FDA-approved compound that acts centrally on melanocortin receptors to modulate sexual desire, rather than peripherally on blood flow like PDE5 inhibitors (sildenafil, tadalafil).
PSI Assessment
The only FDA-approved medication that targets sexual desire through the central nervous system rather than peripheral blood flow is PT-141, sold as Vyleesi. Approved in 2019 for hypoactive sexual desire disorder in premenopausal women, it activates melanocortin receptors in the brain's hypothalamus to modulate the neurological pathways controlling arousal and desire. The Phase III trials demonstrated statistically significant improvements. The clinical profile includes a modest effect size and a 40% nausea rate that define its practical use.
The only FDA-approved medication that targets sexual desire through the central nervous system. A distinct mechanism from every other approved sexual health drug.
The mechanism is melanocortin-4 receptor activation in the hypothalamus, which modulates sexual desire through downstream dopaminergic and oxytocinergic signaling. This is fundamentally different from PDE5 inhibitors (sildenafil, tadalafil) that increase blood flow to enable erection. PT-141 was derived from Melanotan II, a non-selective melanocortin agonist originally studied for tanning, by structurally isolating the pro-sexual effect while reducing melanogenic activity.
What the evidence supports
FDA-approved for HSDD in premenopausal women. The only approved medication targeting desire through central melanocortin receptor activation. Phase III trials demonstrated statistically significant efficacy.
What is not yet established
Efficacy in postmenopausal women or men. Whether the modest effect size is clinically meaningful for all patients. Long-term efficacy with repeated use. Whether the male ED Phase II data would have supported approval.
Research Evidence
The findings below cover what the RECONNECT program established and the notable gap in male erectile dysfunction research.
Evidence by condition
Evidence dimensions across PT-141's approved and investigated indications. HSDD in premenopausal women has the deepest evidence. Male erectile dysfunction has Phase II data only.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| HSDD in Premenopausal Women | ||||
| Male Erectile Dysfunction | ||||
| Melanocortin Research |
The RECONNECT Phase III program enrolled more than 1,200 premenopausal women with acquired, generalized HSDD across two randomized placebo-controlled trials over 24 weeks. Statistically significant improvement in desire domain scores. Approximately 0.4 additional satisfying sexual events per month over placebo at the approved dose.
The effect size is modest at the population level. Individual responses vary substantially. The statistical significance drove the FDA approval; the clinical significance is a separate conversation between patient and physician.
Nausea was reported in approximately 40% of participants, the primary tolerability limitation. Other common side effects included flushing and injection-site reactions. The prescribing information limits dosing to once per 24 hours and 8 doses per month.
The nausea rate is the defining practical constraint. It is dose-dependent, typically transient, and does not lead to discontinuation in most patients, but it shapes the clinical conversation about whether the benefit justifies the experience.
Phase II trials in men with erectile dysfunction, including PDE5 inhibitor non-responders, showed positive erectile responses. The male erectile dysfunction program was discontinued before Phase III for commercial reasons, not safety or efficacy failure.
Whether the male erectile dysfunction Phase II data would have supported FDA approval is unknown. The positive signal was never tested in a registrational-quality Phase III trial. This remains one of the notable gaps in the compound's clinical program.
24 Human|39 Animal|50 Reviews
View all 113 indexed studiesHow PT-141 (Bremelanotide) Works
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide derived from Melanotan II, engineered to selectively activate melanocortin-4 receptors in the brain while reducing the melanogenic (tanning) activity of its parent compound.
Most medications for sexual dysfunction work by increasing blood flow to the genitals. PT-141 works differently: it acts in the brain itself, activating receptors in the hypothalamus that influence the neurological pathways controlling sexual desire and arousal. Instead of making the physical response easier, it works on the desire that initiates the response in the first place.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Bremelanotide activates melanocortin-4 receptors (MC4R) in the hypothalamus. MC4R activation modulates downstream dopaminergic and oxytocinergic neural pathways involved in sexual arousal and desire. The compound was derived from Melanotan II (a non-selective melanocortin agonist) by structural modification to enhance MC4R selectivity. Unlike PDE5 inhibitors that act peripherally on vascular smooth muscle, bremelanotide acts centrally on the neurological circuits that initiate and sustain sexual desire.
What is PT-141 (Bremelanotide) being studied for?
Researchers are studying PT-141 (Bremelanotide) across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for PT-141 (Bremelanotide) overall. This means a compound can have human studies for one condition but only animal data for another.
HSDD in Premenopausal Women
·FDA ApprovedThe RECONNECT Phase III program demonstrated statistically significant improvement in desire domain scores and reduction in distress in more than 1,200 premenopausal women. FDA-approved as Vyleesi for this indication.
Limitations: Effect size is modest at the population level (approximately 0.4 additional satisfying sexual events per month over placebo). Nausea rate of approximately 40%. Efficacy in postmenopausal women not established.
Male Erectile Dysfunction
·Human TrialsPhase II trials showed positive erectile responses in men with erectile dysfunction, including PDE5 inhibitor non-responders. The male erectile dysfunction program was discontinued before Phase III.
Limitations: Phase II only. No registrational-quality Phase III trial. The program was discontinued for commercial reasons. Whether the Phase II data would have supported approval is unknown.
Melanocortin Research
·Animal StudiesAnimal studies and early clinical research into broader melanocortin-pathway effects beyond sexual function, including appetite regulation and stress responses.
Limitations: Exploratory. No clinical indication pursued beyond HSDD. The melanocortin pathway is broad, but PT-141's development focused narrowly on sexual desire.
Safety and Regulatory Status
FDA Status: FDA-approved as Vyleesi (bremelanotide) for HSDD in premenopausal women. Approved 2019.
Prescription status: Prescription-only. Subcutaneous self-injection, as needed. Dosing limited to once per 24 hours and 8 doses per month per prescribing information.
Contraindications: Not recommended for patients with uncontrolled hypertension or cardiovascular disease. Transient blood pressure increases observed.
Nausea is the most common side effect (approximately 40%). Flushing, headache, and injection-site reactions are also documented. Transient blood pressure and heart rate increases have been observed, leading to the cardiovascular precaution in the prescribing information.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a PT-141 (Bremelanotide) discussion.
Comparison and Related Research
PT-141 is most often compared with PDE5 inhibitors (which act peripherally on blood flow) and with Melanotan II (its parent compound). The comparisons below outline how each differs.
Head-to-head comparisons
Full research comparisons covering PT-141 (Bremelanotide) and another peptide side by side.
PT-141 (Bremelanotide) vs Oxytocin
PT-141 is FDA-approved for sexual desire. Oxytocin is studied for bonding and broader neuroendocrine effects. Evidence-graded comparison.
View full comparisonPT-141 (Bremelanotide) vs Kisspeptin
Kisspeptin triggers GnRH release for reproductive function. PT-141 activates melanocortin receptors for sexual desire. Evidence-graded comparison.
View full comparisonRelated compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.The RECONNECT Phase III program. Two randomized placebo-controlled trials in 1,247 premenopausal women with acquired hypoactive sexual desire disorder. Statistically significant improvement in desire domain scores. Basis for the 2019 FDA approval of Vyleesi.Kingsberg SA et al., 2019 in Obstet Gynecol. View on PubMed
- 2.Phase IIb dose-finding trial that established the 1.75 mg subcutaneous dose used in Phase III. Demonstrated dose-response relationship for the desire and arousal endpoints.Clayton AH et al., 2016 in Womens Health. View on PubMed
- 3.52-week open-label extension of the RECONNECT program. Sustained effect and safety profile across a year of as-needed dosing.Simon JA et al., 2019 in Obstet Gynecol. View on PubMed
- 4.Foundational preclinical work establishing that melanocortin-4 receptor activation selectively enhances female sexual motivation in animal models. Mechanistic basis for the clinical development program.Pfaus JG et al., 2007 in Pharmacol Biochem Behav. View on PubMed
- 5.Early Phase II work in female sexual arousal disorder. Supported the broader development program that ultimately focused on HSDD.Safarinejad MR, 2008 in J Urol. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.